Delivering the promise of small ncRNA therapeutics

Therapeutic Delivery

Volumn 5, Issue 5, 2014, Pages 569-589

  Miller, Andrew D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL UNTRANSLATED RNA; SOLID LIPID NANOPARTICLE; UNTRANSLATED RNA;

DRUG DELIVERY SYSTEM; GENE THERAPY; HUMAN; NONHUMAN; ORGANIC CHEMISTRY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; RNA VECTOR;

ANIMALS; GENE TRANSFER TECHNIQUES; HUMANS; INDIVIDUALIZED MEDICINE; LIPIDS; NANOPARTICLES; RNA INTERFERENCE; RNA, SMALL UNTRANSLATED;

EID: 84904004156     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.14.23     Document Type: Review

References (144)

1. Dykxhoorn DM, Lieberman J. Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs. Annu. Rev. Biomed. Eng. 8, 377-402 (2006).
2. Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther. 13(6), 541-552 (2006).
3. De Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6(6), 443-453 (2007).
4. Tripp RA, Tompkins SM. Therapeutic applications of RNAi for silencing virus replication. Methods Mol. Biol. 555, 43-61 (2009).
5. Bratkovic T, Rogelj B. Biology and applications of small nucleolar RNAs. Cell. Mol. Life Sci. 68(23), 3843-3851 (2011).
6. Collins LJ. Characterizing ncRNAs in human pathogenic protists using high-throughput sequencing technology. Front. Genet. 2, 96 (2011).
7. Holley CL, Topkara VK. An introduction to small non-coding RNAs: miRNA and snoRNA. Cardiovasc. Drugs Ther. 25(2), 151-159 (2011).
8. Makarova JA, Kramerov DA. SNOntology: myriads of novel SnoRNAs or just a mirage? BMC Genomics 12(1), 543 (2011).
9. Scott MS, Ono M. From snoRNA to miRNA: dual function regulatory non-coding RNAs. Biochimie 93(11), 1987-1992 (2011).
10. Esteller M. Non-coding RNAs in human disease. Nat. Rev. Genet. 12(12), 861-874 (2011).
11. Tsujiuchi T, Wakabayashi T, Miller AD, Natsume A. RNA interference therapeutics for tumour therapy: promising work in progress. In:Gene Therapy of Cancer (3rd Edition) . Lattime EC, Gerson SL (Eds). Academic Press, 393-408 (2014).
12. Barrangou R. CRISPR-Cas systems and RNA-guided interference. Wiley Interdiscip. Rev. RNA 4(3), 267-278 (2013).
13. Gaj T, Gersbach CA, Barbas CF 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31(7), 397-405 (2013).
14. Reeks J, Naismith JH, White MF. CRISPR interference: a structural perspective. Biochem. J. 453(2), 155-166 (2013).
15. Richter H, Randau L, Plagens A. Exploiting CRISPR/Cas: interference mechanisms and applications. Int. J. Mol. Sci. 14(7), 14518-14531 (2013).
16. Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J. Clin. Invest. 117(12), 3623-3632 (2007).
17. De Paula D, Bentley MV, Mahato RI. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 13(4), 431-456 (2007).
18. Gao K, Huang L. Nonviral methods for siRNA delivery. Mol. Pharm. 6(3), 651-658 (2009).
19. Tseng YC, Mozumdar S, Huang L. Lipid-based systemic delivery of siRNA. Adv. Drug Deliv. Rev. 61(9), 721-731 (2009).
20. Hickerson RP, Vlassov AV, Wang Q et al. Stability study of unmodified siRNA and relevance to clinical use. Oligonucleotides 18(4), 345-354 (2008).
21. Morin A, Gallou-Kabani C, Mathieu JR, Cabon F. Systemic delivery and quantification of unformulated interfering RNAs in vivo. Curr. Top. Med. Chem. 9(12), 1117-1129 (2009).
22. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8(2), 129-138 (2009).
23. Cheng K, Mahato RI. siRNA delivery and targeting. Mol. Pharm. 6(3), 649-650 (2009).
24. Fattal E, Bochot A. State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. Int. J. Pharm. 364(2), 237-248 (2008).
25. Fenske DB, Chonn A, Cullis PR. Liposomal nanomedicines: an emerging field. Toxicol. Pathol. 36(1), 21-29 (2008).
26. Fenske DB, Cullis PR. Liposomal nanomedicines. Expert Opin. Drug Deliv. 5(1), 25-44 (2008).
27. Li SD, Huang L. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances. Curr. Opin. Investig. Drugs 9(12), 1317-1323 (2008).
28. Li W, Szoka FC Jr. Lipid-based nanoparticles for nucleic acid delivery. Pharm. Res. 24(3), 438-449 (2007).
29. Philipp A, Meyer M, Wagner E. Extracellular targeting of synthetic therapeutic nucleic acid formulations. Curr. Gene Ther. 8(5), 324-334 (2008).
30. Wu SY, McMillan NA. Lipidic systems for in vivo siRNA delivery. AAPS J. 11(4), 639-652 (2009).
31. Jeong JH, Mok H, Oh YK, Park TG. siRNA conjugate delivery systems. Bioconjug. Chem. 20(1), 5-14 (2009).
32. Jere D, Arote R, Jiang HL, Kim YK, Cho MH, Cho CS. Bioreducible polymers for efficient gene and siRNA delivery. Biomed. Mater. 4(2), 25020 (2009).
33. Kim SS, Garg H, Joshi A, Manjunath N. Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol. Med. 15(11), 491-500 (2009).
34. Kostarelos K, Miller AD. Synthetic, self-assembly ABCD nanoparticles; a structural paradigm for viable synthetic non-viral vectors. Chem. Soc. Rev. 34(11), 970-994 (2005).
35. Kurreck J. RNA interference: from basic research to therapeutic applications. Angew. Chem. Int. Ed. Engl. 48(8), 1378-1398 (2009).
36. Miller AD. Towards safe nanoparticle technologies for nucleic acid therapeutics. Tumori 94(2), 234-245 (2008).
37. Miller AD. Synthetic nucleic acid delivery systems in gene therapy. In: Encyclopedia of Life Sciences. doi:10.1002/9780470015902.a0005745.pub2 Wiley & Sons, Chichester, UK (2008).
38. Thanou M, Waddington S, Miller AD. Gene therapy. In:Comprehensive Medicinal Chemistry II . Taylor JB, Triggle DJ (Eds). Elsevier, Oxford, UK, 297-320 (2007).
39. Miller AD. Delivery of RNAi therapeutics: work in progress. Expert Rev. Med. Devices 10(6), 781-811 (2013).
40. Escriou V, Mignet N, Miller AD. Auto-associative lipid-based systems for nonviral nucleic acid delivery. In:Advanced Textbook on Gene Transfer, Gene Therapy and Genetic Pharmacology . Scherman D (Ed.). Imperial College Press, London, UK, 221-254 (2014).
41. Miller AD. The problem with cationic liposome/micelle-based non-viral vector systems for gene therapy. Curr. Med. Chem. 10(14), 1195-1211 (2003).
42. Zhang YP, Sekirov L, Saravolac EG et al. Stabilized plasmid-lipid particles for regional gene therapy: formulation and transfection properties. Gene Ther. 6(8), 1438-1447 (1999).
43. Wheeler JJ, Palmer L, Ossanlou M et al. Stabilized plasmid-lipid particles: construction and characterization. Gene Ther. 6(2), 271-281 (1999).
44. Mok KW, Lam AM, Cullis PR. Stabilized plasmid-lipid particles: factors influencing plasmid entrapment and transfection properties. Biochim. Biophys. Acta 1419(2), 137-150 (1999).
45. Morrissey DV, Lockridge JA, Shaw L et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23(8), 1002-1007 (2005).
46. Zimmermann TS, Lee AC, Akinc A et al. RNAi-mediated gene silencing in non-human primates. Nature 441(7089), 111-114 (2006).
47. Semple SC, Akinc A, Chen J et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28(2), 172-176 (2010).
48. Basha G, Novobrantseva TI, Rosin N et al. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol. Ther. 19(12), 2186-2200 (2011).
49. Lee JB, Zhang K, Tam YY et al. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo. Int. J. Cancer 131(5), E781-E790 (2012).
50. Jayaraman M, Ansell SM, Mui BL et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. Engl. 51(34), 8529-8533 (2012).
51. Bisgaier CL, Siebenkas MV, Williams KJ. Effects of apolipoproteins A-IV and A-I on the uptake of phospholipid liposomes by hepatocytes. J. Biol. Chem. 264(2), 862-866 (1989).
52. Abrams MT, Koser ML, Seitzer J et al. Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol. Ther. 18(1), 171-180 (2010).
53. Crawford R, Dogdas B, Keough E et al. Analysis of lipid nanoparticles by Cryo-EM for characterizing siRNA delivery vehicles. Int. J. Pharm. 403(1-2), 237-244 (2011).
54. Pei Y, Hancock PJ, Zhang H et al. Quantitative evaluation of siRNA delivery in vivo. RNA 16(12), 2553-2563 (2010).
55. Tao W, Mao X, Davide JP et al. Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses. Mol. Ther. 19(3), 567-575 (2011).
56. Santel A, Aleku M, Keil O et al. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther. 13(18), 1360-1370 (2006).
57. Santel A, Aleku M, Keil O et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 13(16), 1222-1234 (2006).
58. Aleku M, Schulz P, Keil O et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res. 68(23), 9788-9798 (2008).
59. Adami RC, Seth S, Harvie P et al. An amino acid-based amphoteric liposomal delivery system for systemic administration of siRNA. Mol. Ther. 19(6), 1141-1151 (2011).
60. Sonoke S, Ueda T, Fujiwara K et al. Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes. Cancer Res. 68(21), 8843-8851 (2008).
61. Dudek H, Wong DH, Arvan R et al. Knockdown of beta-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo. Mol. Ther. 22(1), 92-101 (2014).
62. Yoshizawa T, Hattori Y, Hakoshima M, Koga K, Maitani Y. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. Eur. J. Pharm. Biopharm. 70(3), 718-725 (2008).
63. Li SD, Huang L. Surface-modified LPD nanoparticles for tumor targeting. Ann. N. Y. Acad. Sci. 1082, 1-8 (2006).
64. Li SD, Huang L. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol. Pharm. 3(5), 579-588 (2006).
65. Chono S, Li SD, Conwell CC, Huang L. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J. Control. Release 131(1), 64-69 (2008).
66. Chen Y, Sen J, Bathula SR, Yang Q, Fittipaldi R, Huang L. Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol. Pharm. 6(3), 696-705 (2009).
67. Li SD, Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim. Biophys Acta 1788(10), 2259-2266 (2009).
68. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319(5863), 627-630 (2008).
69. Peer D, Shimaoka M. Systemic siRNA delivery to leukocyte-implicated diseases. Cell Cycle 8(6), 853-859 (2009).
70. Srinivasan C, Peer D, Shimaoka M. Integrin-targeted stabilized nanoparticles for an efficient delivery of siRNAs in vitro and in vivo. Methods Mol. Biol. 820, 105-116 (2012).
71. Carmona S, Jorgensen MR, Kolli S et al. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol. Pharm. 6(3), 706-717 (2009).
72. Kolli S, Wong SP, Harbottle R, Johnston B, Thanou M, Miller AD. pH-Triggered nanoparticle mediated delivery of siRNA to liver cells in vitro and in vivo. Bioconjug. Chem. 24(3), 314-332 (2013).
73. Kenny GD, Kamaly N, Kalber TL et al. Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo. J. Control. Release 149(2), 111-116 (2011).
74. Aissaoui A, Chami M, Hussein M, Miller AD. Efficient topical delivery of plasmid DNA to lung in vivo mediated by putative triggered, PEGylated pDNA nanoparticles. J. Control. Release 154(3), 275-284 (2011).
75. Kamaly N, Kalber T, Ahmad A et al. Bimodal paramagnetic and fluorescent liposomes for cellular and tumor magnetic resonance imaging. Bioconjug. Chem. 19(1), 118-129 (2008).
76. Kamaly N, Kalber T, Thanou M, Bell JD, Miller AD. Folate receptor targeted bimodal liposomes for tumor magnetic resonance imaging. Bioconjug. Chem. 20(4), 648-655 (2009).
77. Kamaly N, Kalber T, Kenny G, Bell J, Jorgensen M, Miller A. A novel bimodal lipidic contrast agent for cellular labelling and tumour MRI. Org. Biomol. Chem. 8(1), 201-211 (2010).
78. Drake CR, Aissaoui A, Argyros O, Thanou M, Steinke JH, Miller AD. Examination of the effect of increasing the number of intra-disulfide amino functional groups on the performance of small molecule cyclic polyamine disulfide vectors. J. Control. Release 171(1), 81-90 (2013).
79. Stewart L, Manvell M, Hillery E et al. Physico-chemical analysis of cationic liposome-DNA complexes (lipoplexes) with respect to in vitro and in vivo gene delivery efficiency. J. Chem. Soc., Perkin Trans. 2, 624-632 (2001).
80. Chen J, Jorgensen MR, Thanou M, Miller AD. Post-coupling strategy enables true receptor-targeted nanoparticles. J. RNAi Gene Silencing 7, 449-455 (2011).
81. Wang M, Lowik DW, Miller AD, Thanou M. Targeting the urokinase plasminogen activator receptor with synthetic self-assembly nanoparticles. Bioconjug. Chem. 20(1), 32-40 (2009).
82. Wang M, Miller AD, Thanou M. Effect of surface charge and ligand organization on the specific cell-uptake of uPAR-targeted nanoparticles. J. Drug Target. 21(7), 684-692 (2013).
83. Keller M, Harbottle RP, Perouzel E et al. Nuclear localisation sequence templated nonviral gene delivery vectors. investigation of intracellular trafficking events of LMD and LD vector systems. Chembiochem 4(4), 286-298 (2003).
84. Guo X, Szoka FC Jr. Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG - diortho ester - lipid conjugate. Bioconjug. Chem. 12(2), 291-300 (2001).
85. Walker GF, Fella C, Pelisek J et al. Toward synthetic viruses: endosomal pH-triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo. Mol. Ther. 11(3), 418-425 (2005).
86. Mudhakir D, Akita H, Tan E, Harashima H. A novel IRQ ligand-modified nano-carrier targeted to a unique pathway of caveolar endocytic pathway. J. Control. Release 125(2), 164-173 (2008).
87. Hatakeyama H, Ito E, Akita H et al. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. J. Control. Release 139(2), 127-132 (2009).
88. Hatakeyama H, Akita H, Kogure K et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther. 14(1), 68-77 (2007).
89. Zhang JX, Zalipsky S, Mullah N, Pechar M, Allen TM. Pharmaco attributes of dioleoylphosphatidylethanolamine/ cholesterylhemisuccinate liposomes containing different types of cleavable lipopolymers. Pharmacol. Res. 49(2), 185-198 (2004).
90. Yingyuad P, Mevel M, Prata C et al. Enzyme-triggered PEGylated pDNA-nanoparticles for controlled release of pDNA in tumors. Bioconjug. Chem. 24(3), 343-362 (2013).
91. Yingyuad P, Mével M, Prata C, Kontogiorgis C, Thanou M, Miller AD. Enzyme-triggered PEGylated siRNA-nanoparticles for controlled release of siRNA. J. RNAi Gene Silencing 10, 490-499 (2014).
92. Drake CR, Aissaoui A, Argyros O et al. Bioresponsive small molecule polyamines as non-cytotoxic alternative to polyethylenimine. Mol. Pharm. 7(6), 2040-2055 (2010).
93. Zalipsky S, Qazen M, Walker JA 2nd, Mullah N, Quinn YP, Huang SK. New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. Bioconjug. Chem. 10(5), 703-707 (1999).
94. Song S, Liu D, Peng J et al. Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo. FASEB J. 23(5), 1396-1404 (2009).
95. Akinc A, Querbes W, De S et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18(7), 1357-1364 (2010).
96. Andreu A, Fairweather N, Miller AD. Clostridium neurotoxin fragments as potential targeting moieties for liposomal gene delivery to the CNS. Chembiochem 9(2), 219-231 (2008).
97. Waterhouse JE, Harbottle RP, Keller M et al. Synthesis and Application of integrin targeting lipopeptides in targeted gene delivery. Chembiochem 6(7), 1212-1223 (2005).
98. Cardoso AL, Simoes S, De Almeida LP et al. Tf-lipoplexes for neuronal siRNA delivery: a promising system to mediate gene silencing in the CNS. J. Control. Release 132(2), 113-123 (2008).
99. Tietze N, Pelisek J, Philipp A et al. Induction of apoptosis in murine neuroblastoma by systemic delivery of transferrin-shielded siRNA polyplexes for downregulation of RNA. Oligonucleotides 18(2), 161-174 (2008).
100. Pirollo KF, Zon G, Rait A et al. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum. Gene Ther. 17(1), 117-124 (2006).
101. Harbottle RP, Cooper RG, Hart SL et al. An RGD-oligolysine peptide: a prototype construct for integrin-mediated gene delivery. Hum. Gene Ther. 9(7), 1037-1047 (1998).
102. Temming K, Schiffelers RM, Molema G, Kok RJ. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist. Updat. 8(6), 381-402 (2005).
103. Sato A, Takagi M, Shimamoto A, Kawakami S, Hashida M. Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials 28(7), 1434-1442 (2007).
104. Chu T, Ebright J, Ellington AD. Using aptamers to identify and enter cells. Curr. Opin. Mol. Ther. 9(2), 137-144 (2007).
105. Chu TC, Twu KY, Ellington AD, Levy M. Aptamer mediated siRNA delivery. Nucleic Acids Res. 34(10), e73 (2006).
106. Overhoff M, Sczakiel G. Phosphorothioate-stimulated uptake of short interfering RNA by human cells. EMBO Rep. 6(12), 1176-1181 (2005).
107. Fluiter K, Mook OR, Baas F. The therapeutic potential of LNA-modified siRNAs: reduction of off-target effects by chemical modification of the siRNA sequence. Methods Mol. Biol. 487, 189-203 (2009).
108. Gao S, Dagnaes-Hansen F, Nielsen EJ et al. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol. Ther. 17(7), 1225-1233 (2009).
109. Glud SZ, Bramsen JB, Dagnaes-Hansen F et al. Naked siLNA-mediated gene silencing of lung bronchoepithelium EGFP expression after intravenous administration. Oligonucleotides 19(2), 163-168 (2009).
110. Elmen J, Lindow M, Schutz S et al. LNA-mediated microRNA silencing in non-human primates. Nature 452(7189), 896-899 (2008).
111. Obad S, Dos Santos CO, Petri A et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nature Genet. 43(4), 371-378 (2011).
112. Straarup EM, Fisker N, Hedtjarn M et al. Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res. 38(20), 7100-7111 (2010).
113. Coelho T, Adams D, Silva A et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369(9), 819-829 (2013).
114. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, Phase 1 trial. Lancet 383(9911), 60-68 (2014).
115. Oliver M, Ahmad A, Kamaly N et al. MAGfect: a novel liposome formulation for MRI labelling and visualization of cells. Org. Biomol. Chem. 4(18), 3489-3497 (2006).
116. Miller AD. Lipid-based nanoparticles in cancer diagnosis and therapy. J. Drug Deliv. 2013, 165981 (2013).
117. Birchall J. Pulmonary delivery of nucleic acids. Expert Opin. Drug Deliv. 4(6), 575-578 (2007).
118. Thomas M, Lu JJ, Chen J, Klibanov AM. Non-viral siRNA delivery to the lung. Adv. Drug Deliv. Rev. 59(2-3), 124-133 (2007).
119. Boado RJ. Blood-brain barrier transport of non-viral gene and RNAi therapeutics. Pharm. Res. 24(9), 1772-1787 (2007).
120. Svensson RU, Shey MR, Ballas ZK et al. Assessing siRNA pharmacodynamics in a luciferase-expressing mouse. Mol. Ther. 16(12), 1995-2001 (2008).
121. Chen AA, Derfus AM, Khetani SR, Bhatia SN. Quantum dots to monitor RNAi delivery and improve gene silencing. Nucleic Acids Res. 33(22), e190 (2005).
122. Bonoiu A, Mahajan SD, Ye L et al. MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res. 1282, 142-155 (2009).
123. Walther C, Meyer K, Rennert R, Neundorf I. Quantum dot-carrier peptide conjugates suitable for imaging and delivery applications. Bioconjug. Chem. 19(12), 2346-2356 (2008).
124. Johnson LN, Cashman SM, Kumar-Singh R. Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea. Mol. Ther. 16(1), 107-114 (2008).
125. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl Acad. Sci. USA 104(39), 15549-15554 (2007).
126. Medarova Z, Pham W, Farrar C, Petkova V, Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nat. Med. 13(3), 372-377 (2007).
127. Mikhaylova M, Stasinopoulos I, Kato Y, Artemov D, Bhujwalla ZM. Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA. Cancer Gene Ther. 16(3), 217-226 (2009).
128. Yezhelyev MV, Qi L, O'Regan RM, Nie S, Gao X. Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging. J. Am. Chem. Soc. 130(28), 9006-9012 (2008).
129. Laufer SD, Restle T. Peptide-mediated cellular delivery of oligonucleotide-based therapeutics in vitro: quantitative evaluation of overall efficacy employing easy to handle reporter systems. Curr. Pharm. Des. 14(34), 3637-3655 (2008).
130. Mescalchin A, Detzer A, Wecke M, Overhoff M, Wunsche W, Sczakiel G. Cellular uptake and intracellular release are major obstacles to the therapeutic application of siRNA: novel options by phosphorothioate-stimulated delivery. Expert Opin. Biol. Ther. 7(10), 1531-1538 (2007).
131. Detzer A, Overhoff M, Mescalchin A, Rompf M, Sczakiel G. Phosphorothioate-stimulated cellular uptake of siRNA: a cell culture model for mechanistic studies. Curr. Pharm. Des. 14(34), 3666-3673 (2008).
132. Detzer A, Overhoff M, Wunsche W et al. Increased RNAi is related to intracellular release of siRNA via a covalently attached signal peptide. RNA 15(4), 627-636 (2009).
133. Detzer A, Sczakiel G. Phosphorothioate-stimulated uptake of siRNA by mammalian cells: a novel route for delivery. Curr. Top. Med. Chem. 9(12), 1109-1116 (2009).
134. White PJ. Barriers to successful delivery of short interfering RNA after systemic administration. Clin. Exp. Pharmacol. Physiol. 35(11), 1371-1376 (2008).
135. Wolff JA, Rozema DB. Breaking the bonds: non-viral vectors become chemically dynamic. Mol. Ther. 16(1), 8-15 (2008).
136. Lundberg P, El-Andaloussi S, Sutlu T, Johansson H, Langel U. Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J. 21(11), 2664-2671 (2007).
137. Heyes J, Palmer L, Bremner K, Maclachlan I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control. Release 107(2), 276-287 (2005).
138. Lavigne C, Thierry AR. Specific subcellular localization of siRNAs delivered by lipoplex in MCF-7 breast cancer cells. Biochimie 89(10), 1245-1251 (2007).
139. Buyens K, Meyer M, Wagner E, Demeester J, De Smedt SC, Sanders NN. Monitoring the disassembly of siRNA polyplexes in serum is crucial for predicting their biological efficacy. J. Control. Release 141(1), 38-41 (2010).
140. Kraljevic S, Pavelic K. Navigare necessere est. Improved navigation would help to solve two crucial problems in modern drug therapy: toxicity and precise delivery. EMBO Rep. 6(8), 695-700 (2005).
141. Omidi Y, Barar J, Akhtar S. Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray technology. Curr. Drug Deliv. 2(4), 429-441 (2005).
142. Bonnet ME, Erbacher P, Bolcato-Bellemin AL. Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response. Pharm. Res. 25(12), 2972-2982 (2008).
143. Maclachlan I, Judge A: US2007/0054873 (2007).
144. Bumcrot D: PCT/US2009/036223 (2009).